BrightSpring Health Services, Inc. (BTSG) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session reflect a positive sentiment overall. The company has strong revenue growth projections, especially in specialty pharmacy and infusion markets. They anticipate margin expansion through operational efficiencies and investments in AI. Despite some headwinds from IRA changes, the company expects strong EBITDA growth and is optimistic about the home health and hospice sectors. The integration of acquired assets and cash-funded acquisitions indicate a robust financial position. Management's responses were generally positive, although some specifics were lacking, which slightly tempers the overall sentiment.
Key Financial Performance
Total Company Revenue (2025) $12.9 billion, representing 28% year-over-year growth. This growth was driven by Pharmacy Solutions revenue of $11.4 billion (31% year-over-year growth) and Provider Services revenue of $1.5 billion (11% year-over-year growth).
Adjusted EBITDA (2025) $618 million, representing 34% year-over-year growth. The increase was primarily driven by cost efficiencies from procurement and operational initiatives, along with a generic revenue mix shift in Pharmacy.
Adjusted EBITDA Margin (2025) 4.8%, a 20 basis point increase versus 2024, primarily driven by cost efficiencies and operational initiatives.
Cash Flow from Operations (2025) $490 million, with leverage declining to 2.99x as of December 31, 2025, from 4.16x as of December 31, 2024. This improvement was due to strong operating cash flows and adjusted EBITDA growth.
Pharmacy Solutions Revenue (Q4 2025) $3.2 billion, achieving 32% year-over-year growth. Infusion and specialty revenue was $2.6 billion (43% growth), while home and community pharmacy revenue was $593 million (1% decline due to customer bankruptcy and exiting uneconomic customers).
Provider Services Revenue (Q4 2025) $394 million, representing 13% year-over-year growth. Home health care revenue grew 19% to $217 million, rehab revenue grew 8% to $75 million, and personal care revenue grew 4% to $102 million.
Gross Profit (2025) $1.5 billion, representing 20% year-over-year growth. Fourth quarter gross profit was $413 million, a 22% increase compared to the same period last year.
Leverage Ratio (2025) 2.99x as of December 31, 2025, down from 4.16x as of December 31, 2024, due to adjusted EBITDA growth and strong operating cash flows.
Pharmacy Solutions Adjusted EBITDA (Q4 2025) $162 million, a 44% increase compared to last year, with an adjusted EBITDA margin of 5.1% (up 40 basis points).
Provider Services Adjusted EBITDA (Q4 2025) $64 million, a 16% increase compared to last year, with an adjusted EBITDA margin of 16.4% (up 50 basis points).
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Acquisition of Amedisys and LHC home health assets: BrightSpring acquired 107 branches for $239 million, generating $345 million in pro forma revenue for 2025. These assets complement the existing home health business geographically and align with hospice locations.
Limited Distribution Drugs (LDDs): BrightSpring launched 24 new LDDs in 2025, with plans for 16-20+ launches in the next 12-18 months. LDD portfolio now includes 149 drugs.
Market Expansion in Home Health: Home health care revenue grew 19% year-over-year, with an average daily census increase of 15% to nearly 35,000. Growth driven by quality metrics, partnerships, and acquisitions.
Rehab Care Expansion: Rehab care revenue grew 8% year-over-year, with 13% growth in persons served and 17% growth in hours billed for neuro rehab services.
Operational Efficiencies: Procurement initiatives and new technologies enhanced operational efficiencies, contributing to a 34% year-over-year growth in adjusted EBITDA for 2025.
Cash Flow and Leverage: Cash flow from operations reached $490 million in 2025, reducing leverage from 4.16x to 2.99x year-over-year.
Divestiture of Community Living Business: Transaction expected to close in Q1 2026, generating $715 million in net after-tax cash proceeds to be used for debt reduction.
Focus on Home and Community Health: BrightSpring aims to build a scaled platform for home and community health care, emphasizing quality outcomes and operational best practices.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Community Living Divestiture: The divestiture of the Community Living business, while streamlining operations, could pose risks related to the transition process and potential disruptions in operations or financial performance during the transition.
Debt Management: The company plans to use proceeds from the divestiture for debt paydown, but reliance on this strategy could expose the company to financial risks if the proceeds are not sufficient or if other financial challenges arise.
Acquisition Integration: The integration of Amedisys and LHC home health assets, while strategic, could face challenges such as operational inefficiencies, cultural integration issues, or unexpected costs.
Bankruptcy of Large Customer: The bankruptcy of a large customer has led to a decline in home and community pharmacy revenue, and the ongoing bankruptcy process could create further financial uncertainties.
Exiting Uneconomic Customers: The decision to exit specific uneconomic customers could result in short-term revenue declines and potential market share loss.
Operational Efficiency Initiatives: While operational efficiency initiatives are expected to drive cost savings, there is a risk that these initiatives may not deliver the anticipated benefits or could lead to unintended operational disruptions.
Regulatory and Market Risks: Forward-looking statements highlight risks and uncertainties related to regulatory changes and market conditions that could impact financial performance.
Leverage and Financial Flexibility: Although the company has reduced its leverage ratio, maintaining financial flexibility could be challenging if cash flow generation does not meet expectations or if unexpected financial obligations arise.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: BrightSpring expects total revenue to grow approximately 14% year-over-year at the midpoint of the provided range for 2026, with total revenue guidance in the range of $14.45 billion to $15.0 billion.
Adjusted EBITDA Growth: The company anticipates total adjusted EBITDA to grow approximately 25% year-over-year at the midpoint of the provided range for 2026, with guidance in the range of $760 million to $790 million.
Pharmacy Solutions Revenue: Pharmacy Solutions revenue is projected to be between $12.6 billion and $13.1 billion for 2026.
Provider Services Revenue: Provider Services revenue is expected to range from $1.85 billion to $1.9 billion in 2026.
Contribution from Acquisitions: The Amedisys and LHC acquisitions are expected to contribute approximately $30 million to total adjusted EBITDA in 2026.
Operational and Cost Efficiencies: BrightSpring plans to achieve additional gains in 2026 through procurement and operational programs, including cost efficiencies, best practices, and streamlining across all business lines.
Home-Based Primary Care Expansion: The company is investing in resources to expand its home-based primary care business, particularly in alignment with ACO payment strategies.
Limited Distribution Drug (LDD) Launches: BrightSpring expects 16 to 20+ limited distribution drug launches over the next 12 to 18 months, which will drive growth in the specialty and infusion business.
Leverage Ratio Target: The company aims to achieve a leverage ratio of 2.5x or below by mid-2026, excluding acquisitions or other uses of cash.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the points of variability in the company's 2026 outlook?
A:The company sees consistency in Q1 and 2025, focusing on executing strategies like driving volume growth, making sales investments in home health, hospice, infusion, and community markets, and integrating acquisitions like Amedisys and LHC. They also expect benefits from Lean Sigma, tech, and AI projects, along with margin expansion.
Q:What is the company's outlook on LDD introductions and biosimilar conversions?
A:The company won 24 LDDs last year and expects 16-20 new LDD introductions in the next 12-18 months. They are focusing on rare, orphan, and non-oncology LDDs, including infusion and cardiac drugs. Regarding biosimilars, they have minimal exposure, with STELARA mostly in the rearview mirror.
Q:What are the EBITDA and margin expectations for 2026?
A:The company expects broad-based margin expansion driven by initiatives deployed in late 2025 and continuing into 2026. They anticipate favorable product and service mix, operational efficiencies, and continued investments in AI, technologies, and sales. The EBITDA guide for 2026 is 27%-28% at the high end.
Q:What is the company's view on home health rate adjustments?
A:The company is optimistic about home health rates, with a baseline view of flat rates. They see a strong runway for home health and hospice over the next 5-10 years, driven by best-in-class management, sales additions, and technology investments.
Q:What is the impact of generic drug launches on specialty earnings?
A:Generic launches lead to price declines but improve margins as the company negotiates better margins across product classes. Growth in specialty is multifactorial, including brand LDDs, generic conversions, and a growing fee-for-service business.
Q:What are the expectations for EBITDA growth across segments in 2026?
A:The company expects consistent volume and EBITDA growth across segments, with trends similar to 2025. They anticipate sequential growth throughout 2026.
Q:What is the margin profile of the Amedisys assets acquired?
A:The acquired Amedisys assets have a high single-digit margin, which is lower than the company's legacy Provider segment. The company aims to integrate and improve these margins over time through technology investments and operational improvements.
Q:What is the expected cadence of quarters for 2026?
A:Q1 is expected to be the lowest quarter due to fewer days. Sequential growth is anticipated throughout the year, driven by sales investments, de novos, and operational projects. A generic launch in Q2 will also contribute to margin growth.
Q:What are the moving parts in the 2026 Pharmacy revenue guidance?
A:The company faces $600 million in revenue headwinds from IRA impacts and brand-to-generic conversions. Despite this, they expect strong growth across business lines, including LDD growth and strong script growth in home, infusion, and specialty plans.
Q:What is the update on the infusion business?
A:The infusion business is growing, with double-digit growth in the acute segment and significant opportunities in specialty. The company is creating specialty hubs, investing in resources, and expanding AIS presence to drive growth.
Q:What is the role of the Onco360 sales force?
A:The Onco360 sales force plays a key role in LDD launches and generic conversions, maintaining strong relationships with pharma and prescribers. The company continues to invest in this field force to cover all U.S. geographies and provide high service levels.
Q:What are the 2026 Pharmacy segment margin expectations?
A:The company expects a mix shift, operational improvements, and investments to drive margin improvements in the Pharmacy segment. Margins are expected to improve slightly compared to 2025.
Q:What are the integration milestones and value of the Amedisys and LHC acquisitions?
A:The company aims to integrate Amedisys and LHC assets to align with their margin profile and drive growth in attractive markets. They see opportunities for integrated care and benefits for their hospice business. The acquisitions were funded entirely with cash on hand, reflecting the company's strong balance sheet.
Q:What is the impact of IRA changes on the LTC business?
A:The company faces headwinds from IRA changes but is working with payers to achieve enhanced dispensing fees. They are focusing on volume growth, operational efficiencies, and entering attractive end markets like assisted living, hospice, and behavioral health.
Q:What are the drivers of margin expansion in the Pharmacy segment?
A:Margin expansion is driven by operational efficiencies, economies of scale, and a mix shift towards generics. The company continues to focus on strong growth, market share gains, and targeting attractive therapeutic areas.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timeline for achieving margin improvements in the Amedisys assets and the exact impact of operational efficiencies versus generics on margin expansion. Additionally, they did not provide precise numbers for the contribution of the Onco360 sales force to LDD launches or generic conversions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BrightSpring result
Community Living
Home
Ig
Jen
LDD win
LDDs
LHC acquisition
Living acquisition
Provider Services
Services segment
Solutions Provider
acquisition BrightSpring
asset
balance sheet
bankruptcy decision
care Provider
client
community pharmacy
contribution LHC
cost care
cost efficiency
country
customer bankruptcy
day BrightSpring
decline
efficiency practice
end leverage
end market
expansion
flow generation
foundation
gain
home community
individual
midpoint
organization
people investment
platform quality
resource
senior
transaction end
tuck acquisition
BTSG Transcript
BrightSpring Health Services, Inc. (BTSG) Q4 2025 Earnings Call Transcript
Positive2-27
The earnings call summary and Q&A session reflect a positive sentiment overall. The company has strong revenue growth projections, especially in specialty pharmacy and infusion markets. They anticipate margin expansion through operational efficiencies and investments in AI. Despite some headwinds from IRA changes, the company expects strong EBITDA growth and is optimistic about the home health and hospice sectors. The integration of acquired assets and cash-funded acquisitions indicate a robust financial position. Management's responses were generally positive, although some specifics were lacking, which slightly tempers the overall sentiment.
BrightSpring Health Services, Inc. (BTSG) Presents at Bank of America Home Care Conference Transcript
Neutral12-10
BrightSpring Health Services, Inc. (BTSG) Q3 2025 Earnings Call Transcript
Positive10-28
The earnings call summary indicates strong financial performance and optimistic guidance, with a focus on growth in key service lines like infusion and hospice. The company's strategic initiatives, such as AI investments and operational efficiencies, support the positive outlook. The Q&A highlights no significant headwinds and an expectation of sustained growth, with raised EBITDA guidance and a positive market reaction anticipated. Despite some management avoidance in specifics, the overall sentiment is positive, suggesting a likely stock price increase.
BrightSpring Health Services, Inc. (BTSG) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-9
BTSG Slides
BTSG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
